Frontlight ResearchEarly access
Active, not recruitingPhase 3
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
Key facts
- Who runs it
- GC Biopharma Corp
- Where
- Aurora, Centennial, Dallas, Fairfax, and Richmond, United StatesSee the 5 sitesAlso in 2 other countries, 3 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 24 people, planned
- Started
- 21 Dec 2020
- Expected to end
- Nov 2026
- Type of study
- Interventional
- Treatments tested
- GC5107
- Record updated
- 25 July 2025
Who can take part
- Age
- 2 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Subject must be ≥ 2 to < 17 years of age, at the time of signing the informed consent
- Pediatric subject has a confirmed and documented clinical diagnosis of Primary Humoral Immunodeficiency, including hypogammaglobulinemia or agammaglobulinemia
- Subject who has received 300 - 900 mg/kg of IGIV therapy at 21 or 28 day intervals for at least 3 months prior to this study
- Subject who has at least 2 documented plasma IgG trough level of ≥ 500 mg/dL at two infusion cycles (21 or 28 days) within 12 months prior to enrollment
- Subject who is willing to comply with all requirements of the protocol
Who cannot take part
- Subject who has IgA deficiency and is known to have antibodies to IgA
- Subject who has participated in another clinical study (other than an IGIV study) within 3 weeks prior to screening
- Subject who has a history of clinically significant reactions or hypersensitivity to IGIV or other injectable forms of IgG
- Subject who has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency or isolated IgA deficiency, or who has clinically significant impairment of cellular or innate immunity at the discretion of the Investigator
- Subject who has received blood products other than human albumin or human immune globulin within 6 months prior to enrollment
- Subject who has secondary immunodeficiency
Where in United States
Also in 2 other countries, 3 sites
- Children's Hospital ColoradoAurora, United States
- Immunoe Health & Research CentersCentennial, United States
- Allergy Partners of North Texas ResearchDallas, United States
- Lysosomal and Rare Disorders Research and Treatment Center, IncFairfax, United States
- Children's Hospital of Richmond at VCURichmond, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).
The group in the trial
- GC5107Treatment being tested
Immune Globulin Intravenous (Human), 10% Liquid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Evaluate the Pharmacokinetics and Safety of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
- Record updated
- 25 July 2025